Ríos-Santamarina I, García-Domenech R, Gálvez J, Morcillo Esteban J, Santamaría P, Cortijo J. Getting new bronchodilator compounds from molecular topology.
Eur J Pharm Sci 2005;
22:271-7. [PMID:
15196583 DOI:
10.1016/j.ejps.2004.03.013]
[Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2003] [Revised: 03/02/2004] [Accepted: 03/22/2004] [Indexed: 10/26/2022]
Abstract
Molecular topology has been used to select new lead bronchodilator compounds. The main advantage of this method, as compared to others frequently used, is that it does not require a previous explicit knowledge of the mechanism of action (MOA) of the compounds analyzed. A large database (12,000 chemicals) has been examined in this study to find less than 5% compounds with bronchodilator activity. After removing those compounds already described as bronchodilators, we present here the results for 20 among these compounds, some of them showing other pharmacological activities. Some of the compounds selected in this study showed higher relaxation and higher potency than theophylline, which is the reference drug used in the bronchodilator assay performed. For instance, tetrahydro-papaveroline showed significantly higher values than theophylline (93.9% versus 77.0% and pD2=7.30 versus pD2=4.69, respectively). Other compounds, although eliciting small or no relaxation at 0.1mM, produced larger relaxation at higher concentrations (1mM). In conclusion, the molecular topology based approach used in this work has demonstrated to be effective in the search of new bronchodilators.
Collapse